Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 6Active not recruiting 2Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 94Biopsy 60pembrolizumab 58Carboplatin 57Cisplatin 51Nivolumab 47Cyclophosphamide 40Radiotherapy 39Paclitaxel 37Gemcitabine 34Dexamethasone 34Bevacizumab 31Radiation 30atezolizumab 29Pemetrexed 28venetoclax 25olaparib 25Etoposide 25X-Rays 24Prednisone 23Immunoglobulin G 23Doxorubicin 23Disulfides 23Vincristine 22Lenalidomide 22Leucovorin 21Ipilimumab 21durvalumab 20Taxes 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × cabazitaxel × 30 days × Clear all
NCT04592237 2026-06-12

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT03419234 2026-06-03

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
223 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡